miR‑101 inhibits cell proliferation by targeting Rac1 in papillary thyroid carcinoma

Lin,Xiaojie; Guan,Hongyu; Li,Hai; Liu,Liehua; Liu,Juan; Wei,Guohong; Huang,Zhimin; Liao,Zhihong; Li,Yanbing

doi:10.3892/br.2013.192

miR‑101 inhibits cell proliferation by targeting Rac1 in papillary thyroid carcinoma

Authors:
- Xiaojie Lin
- Hongyu Guan
- Hai Li
- Liehua Liu
- Juan Liu
- Guohong Wei
- Zhimin Huang
- Zhihong Liao
- Yanbing Li
View Affiliations

Affiliations: Department of Endocrinology and Diabetes Center, The First Affiliated Hospital of Sun Yat‑sen University, Guangzhou, Guangdong 510080, P.R. China
Published online on: October 31, 2013 https://doi.org/10.3892/br.2013.192
Pages: 122-126

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Accumulating evidence suggests that some microRNAs (miRNAs) are involved in papillary thyroid carcinoma (PTC) progression. However, it remains necessary to elucidate the underlying molecular mechanisms involved. In the present study, we investigated the role of microRNA‑101 (miR‑101) in PTC via targeting of Ras‑related C3 botulinum toxin substrate 1 (Rac1). The results showed that miR‑101 was significantly downregulated in PTC tissues compared with adjacent normal tissues. Restoration of miR‑101 expression significantly inhibited cell proliferation in the K1 PTC cell line. Moreover, algorithm‑based and experimental strategies verified Rac1 as a direct target of miR‑101 in the K1 cell line. Taken together, these findings suggest that miR‑101 inhibited PTC growth via the downregulation of Rac1 expression, providing a better understanding of miRNA‑modulated signaling networks for future cancer therapeutics.

View Figures

View References

1	Lloyd RV, Buehler D and Khanafshar E: Papillary thyroid carcinoma variants. Head Neck Pathol. 5:51–56. 2011. View Article : Google Scholar
2	Singh A, Butuc R and Lopez R: Metastatic papillary thyroid carcinoma with absence of tumor focus in thyroid gland. Am J Case Rep. 14:73–75. 2013. View Article : Google Scholar : PubMed/NCBI
3	Silver CE, Owen RP, Rodrigo JP, et al: Aggressive variants of papillary thyroid carcinoma. Head Neck. 33:1052–1059. 2011. View Article : Google Scholar : PubMed/NCBI
4	Voutilainen PE, Multanen MM, Leppaniemi AK, et al: Prognosis after lymph node recurrence in papillary thyroid carcinoma depends on age. Thyroid. 11:953–957. 2001. View Article : Google Scholar : PubMed/NCBI
5	Chou CK, Chen RF, Chou FF, et al: miR-146b is highly expressed in adult papillary thyroid carcinomas with high risk features including extrathyroidal invasion and the BRAF(V600E) mutation. Thyroid. 20:489–494. 2010. View Article : Google Scholar : PubMed/NCBI
6	Chen PS, Su JL and Hung MC: Dysregulation of microRNAs in cancer. J Biomed Sci. 19:902012. View Article : Google Scholar : PubMed/NCBI
7	O’Day E and Lal A: MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res. 12:2012010.
8	Carvalho J, van Grieken NC, Pereira PM, et al: Lack of microRNA-101 causes E-cadherin functional deregulation through EZH2 up-regulation in intestinal gastric cancer. J Pathol. 228:31–44. 2012.PubMed/NCBI
9	Chandramouli A, Onyeagucha BC, Mercado-Pimentel ME, et al: MicroRNA-101 (miR-101) post-transcriptionally regulates the expression of EP4 receptor in colon cancers. Cancer Biol Ther. 13:175–183. 2012. View Article : Google Scholar : PubMed/NCBI
10	Wang R, Wang HB, Hao CJ, et al: MiR-101 is involved in human breast carcinogenesis by targeting Stathmin1. PLoS One. 7:e461732012. View Article : Google Scholar : PubMed/NCBI
11	Fritz G, Just I and Kaina B: Rho GTPases are over-expressed in human tumors. Int J Cancer. 81:682–687. 1999. View Article : Google Scholar : PubMed/NCBI
12	Silva AL, Carmo F and Bugalho MJ: RAC1b overexpression in papillary thyroid carcinoma: a role to unravel. Eur J Endocrinol. 168:795–804. 2013. View Article : Google Scholar : PubMed/NCBI
13	Lewis-Saravalli S, Campbell S and Claing A: ARF1 controls Rac1 signaling to regulate migration of MDA-MB-231 invasive breast cancer cells. Cell Signal. 25:1813–1819. 2013. View Article : Google Scholar : PubMed/NCBI
14	Guan H, Wei G, Wu J, et al: Down-regulation of miR-218-2 and its host gene SLIT3 cooperate to promote invasion and progression of thyroid cancer. J Clin Endocrinol Metab. 98:E1334–El1344. 2013. View Article : Google Scholar : PubMed/NCBI
15	Liu D, Xia P, Diao D, et al: MiRNA-429 suppresses the growth of gastric cancer cells in vitro. J Biomed Res. 26:389–393. 2012. View Article : Google Scholar : PubMed/NCBI
16	Bartel DP: MicroRNAs: target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
17	Lee YS and Dutta A: MicroRNAs in cancer. Annu Rev Pathol. 4:199–227. 2009. View Article : Google Scholar
18	Zhang B, Pan X, Cobb GP and Anderson TA: microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12. 2007. View Article : Google Scholar : PubMed/NCBI
19	Liu X, He M, Hou Y, et al: Expression profiles of microRNAs and their target genes in papillary thyroid carcinoma. Oncol Rep. 29:1415–1420. 2013.PubMed/NCBI
20	Wu YJ, Tang Y, Li ZF, Li Z, Zhao Y, Wu ZJ and Su Q: Expression and significance of Rac1, Pak1 and Rock1 in gastric carcinoma. Asia Pac J Clin Oncol. Jan 8–2013.(Epub ahead of print). View Article : Google Scholar
21	Schnelzer A, Prechtel D, Knaus U, et al: Rac1 in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b. Oncogene. 19:3013–3020. 2000. View Article : Google Scholar : PubMed/NCBI
22	Jordan P, Brazao R, Boavida MG, Gespach C and Chastre E: Cloning of a novel human Rac1b splice variant with increased expression in colorectal tumors. Oncogene. 18:6835–6839. 1999. View Article : Google Scholar : PubMed/NCBI
23	Liu Y, Wang Y, Zhang Y, et al: Abnormal expression of p120-catenin, E-cadherin, and small GTPases is significantly associated with malignant phenotype of human lung cancer. Lung Cancer. 63:375–382. 2008. View Article : Google Scholar : PubMed/NCBI
24	Bosco EE, Mulloy JC and Zheng Y: Rac1 GTPase: a ‘Rac’ of all trades. Cell Mol Life Sci. 66:370–374. 2009.
25	Sempere LF: Integrating contextual miRNA and protein signatures for diagnostic and treatment decisions in cancer. Expert Rev Mol Diagn. 11:813–827. 2011. View Article : Google Scholar : PubMed/NCBI
26	Swarbrick A, Woods SL, Shaw A, et al: miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma. Nat Med. 16:1134–1140. 2010. View Article : Google Scholar : PubMed/NCBI
27	Cairo S, Wang Y, de Reynies A, et al: Stem cell-like micro-RNA signature driven by Myc in aggressive liver cancer. Proc Natl Acad Sci USA. 107:20471–20476. 2010. View Article : Google Scholar : PubMed/NCBI
28	Cho WC: MicroRNAs in cancer - from research to therapy. Biochim Biophys Acta. 1805:209–217. 2010.PubMed/NCBI
29	Wahid F, Shehzad A, Khan T and Kim YY: MicroRNAs: synthesis, mechanism, function, and recent clinical trials. Biochim Biophys Acta. 1803:1231–1243. 2010. View Article : Google Scholar : PubMed/NCBI